<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="181965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725712</url>
  </required_header>
  <id_info>
    <org_study_id>MET111643</org_study_id>
    <nct_id>NCT00725712</nct_id>
    <nct_alias>NCT00415480</nct_alias>
  </id_info>
  <brief_title>Study of GSK1363089 in Metastatic Gastric Cancer</brief_title>
  <official_title>A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is being conducted at multiple sites to determine the best confirmed
      response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (RECIST) of GSK1363089 on 2 different dosing regimens</measure>
    <time_frame>4 months (average)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events, and clinically significant changes in vital signs and laboratory values</measure>
    <time_frame>4 months (average)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival (PFS) of GSK1363089</measure>
    <time_frame>4 months (average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Stable Disease of GSK1363089</measure>
    <time_frame>4 months (average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak and trough concentrations of GSK1363089 in plasma samples</measure>
    <time_frame>first 8 weeks of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease stabilization rate of GSK 1363089</measure>
    <time_frame>4 months (average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival of GSK1363089</measure>
    <time_frame>6 months (average)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of soluble MET, HGF, soluble VEGFR2 and VEGFA</measure>
    <time_frame>first 8 weeks of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Neoplasms, Gastrointestinal Tract</condition>
  <arm_group>
    <arm_group_label>5-days on/9-days off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing for first 5 days in every 14-day period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>daily dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosed every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1363089 (formerly XL880)</intervention_name>
    <description>c-MET tyrosine kinase inhibitor</description>
    <arm_group_label>daily dosing</arm_group_label>
    <arm_group_label>5-days on/9-days off</arm_group_label>
    <other_name>foretinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed diagnosis of advanced or metastatic gastric carcinoma, or
             adenocarcinoma of the gastroesophageal junction or of the distal esophagus. Subjects
             with tumors of the gastroesophageal junction or of the distal esophagus may be
             eligible provided that the tumor is not of squamous or sarcomatous histology

          -  Measurable disease

          -  The subject consents to provide paired tumor biopsies, directly prior to commencing
             study treatment and then between Days 5 and 8.

          -  The subject has an ECOG performance status ≤2.

          -  The subject is able to ingest the GSK1363089 capsules.

          -  In the adrenocorticotropic hormone (ACTH) stimulation test, the subject has a serum
             cortisol level ≥20 μg/dL (552 nmol/L) 30-90 minutes after injection of ACTH.

          -  The subject has liver, kidney and marrow function.

          -  The subject is capable of understanding and complying with the protocol and has
             signed the informed consent document.

          -  Sexually active subjects (male and female) must use a medically-accepted method of
             contraception during the course of the study.

          -  Female subjects of childbearing potential must have a negative serum pregnancy test
             at screening.

          -  The subject has had no other diagnosis of malignancy (unless non-melanoma skin cancer
             or a malignancy diagnosed ≥5 years ago, and has no evidence of disease for 5 years
             prior to the screening for this study).

          -  QTc &lt; 470 msec.

        Exclusion Criteria:

          -  The subject has received more than two lines of prior cytotoxic chemotherapy for
             locally advanced or metastatic disease. For the purpose of this protocol, neoadjuvant
             therapy would not be considered to be prior cytotoxic chemotherapy. In addition,
             potential subjects who have received prior treatment with c-MET signaling inhibitor
             are excluded.

          -  The subject has received an investigational drug within 14 days of the first dose of
             study drug.

          -  The subject has received chemotherapy, immunotherapy, or radiation therapy (to

             ≥25% of his or her bone marrow) within 14 days or has received nitrosoureas or
             mitomycin C within 6 weeks prior to the scheduled first dose of GSK1363089.

          -  The subject has AEs due to investigational drugs or other medications administered
             more than 21 days prior to enrollment that have not recovered to Grade ≤1 using NCI
             CTCAE v3.0, with the exception of alopecia greater than grade 1.

          -  The subject has known brain metastases.

          -  The subject has uncontrolled intercurrent illness including, but not limited to,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          -  The subject is pregnant or breastfeeding.

          -  The subject is known to be positive for the human immunodeficiency virus (HIV).

          -  The subject has a previously identified allergy or hypersensitivity to components of
             the GSK1363089 formulation.

          -  The subject is unable or unwilling to abide by the study protocol or cooperate fully
             with the investigator or designee.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14.</citation>
    <PMID>23516391</PMID>
  </reference>
  <results_reference>
    <citation>Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancern (GC): Interim results of a multicenter phase II study J Clin Oncol 2009, 27 (15S), 4502.</citation>
  </results_reference>
  <results_reference>
    <citation>Jhawer MP, Kindler HL, Wainberg ZA, Hecht JR, Kerr RO, Ford JM, Henderson C, Mueller T, Keer HN, Shah MA Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase 2 study. J Clin Oncol, 2008, 26 (15S), Abstr. 4572</citation>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 11, 2016</lastchanged_date>
  <firstreceived_date>July 29, 2008</firstreceived_date>
  <firstreceived_results_disposition_date>August 12, 2010</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-Met</keyword>
  <keyword>Metastatic Gastric Carcinoma</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>GSK1363089</keyword>
  <keyword>XL880</keyword>
  <keyword>MET inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>MET111643</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MET111643</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MET111643</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MET111643</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MET111643</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MET111643</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>MET111643</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
